McIlrath & Eck’s Oramed Pharmaceuticals ORMP Stock Holding History

McIlrath & Eck’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.4K	Hold	1,000	–	–	﹤0.01%	1316
2025 Q4	$2.85K	Hold	1,000	–	–	﹤0.01%	851
2025 Q3	$2.64K	Hold	1,000	–	–	﹤0.01%	824
2025 Q2	$2.25K	Hold	1,000	–	–	﹤0.01%	826
2025 Q1	$2.14K	Hold	1,000	–	–	﹤0.01%	826
2024 Q4	$2.42K	Hold	1,000	–	–	﹤0.01%	855
2024 Q3	$2.44K	Sell	1,000 -1,000	-50%	-$2.44K	﹤0.01%	843
2024 Q2	$5.14K	Hold	2,000	–	–	﹤0.01%	712
2024 Q1	$5.84K	Hold	2,000	–	–	﹤0.01%	695
2023 Q4	$4.62K	Hold	2,000	–	–	﹤0.01%	684
2023 Q3	$5.22K	Sell	2,000 -500	-20%	-$1.57K	﹤0.01%	646
2023 Q2	$8.95K	Sell	2,500 -500	-17%	-$1.6K	﹤0.01%	582
2023 Q1	$6.54K	Hold	3,000	–	–	﹤0.01%	615
2022 Q4	$36.1K	Hold	3,000	–	–	0.01%	307
2022 Q3	$19K	Hold	3,000	–	–	0.01%	413
2022 Q2	$14K	Hold	3,000	–	–	﹤0.01%	449
2022 Q1	$26K	Hold	3,000	–	–	0.01%	349
2021 Q4	$43K	Hold	3,000	–	–	0.01%	264
2021 Q3	$66K	Sell	3,000 -1,000	-25%	-$17K	0.02%	200
2021 Q2	$54K	Buy	+4,000	New	+$45.8K	0.02%	222

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Aquamarine Financial George Town $1.37B AUM

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $102M AUM

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

McIlrath & Eck's ORMP Position: Q1 2026 in Review

McIlrath & Eck held its Oramed Pharmaceuticals (ORMP) position steady in Q1 2026 at 1,000 shares worth $3.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1316.

McIlrath & Eck first reported a position in ORMP in Q2 2021 and has held it in 20 quarters since. The position peaked at $66K in Q3 2021. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

McIlrath & Eck held 1,000 shares of Oramed Pharmaceuticals worth $3.4K as of Q1 2026.
McIlrath & Eck left its Oramed Pharmaceuticals share count unchanged in Q1 2026.
Oramed Pharmaceuticals made up ﹤0.01% of McIlrath & Eck's portfolio in Q1 2026, its #1316 holding.
McIlrath & Eck first reported a position in Oramed Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
McIlrath & Eck's Oramed Pharmaceuticals position peaked at $66K in Q3 2021.
64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.